R9281
Rotigotine hydrochloride
≥98% (HPLC)
别名:
(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H25NOS·HCl
化学文摘社编号:
分子量:
351.93
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
SMILES string
Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2
InChI key
CEXBONHIOKGWNU-NTISSMGPSA-N
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
DMSO: >10 mg/mL
originator
UCB Inc.
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.
Features and Benefits
This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Nikos Gorgoraptis et al.
Brain : a journal of neurology, 135(Pt 8), 2478-2491 (2012-07-05)
Hemispatial neglect following right-hemisphere stroke is a common and disabling disorder, for which there is currently no effective pharmacological treatment. Dopamine agonists have been shown to play a role in selective attention and working memory, two core cognitive components of
Santiago Perez-Lloret et al.
Fundamental & clinical pharmacology, 27(1), 81-95 (2012-02-11)
Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMEA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease (PD) or with moderate to severe
Lawrence W Elmer et al.
Parkinsonism & related disorders, 18(5), 488-493 (2012-02-14)
This prospective, open-label extension (SP702; NCT00594165) of a 6-month double-blind, randomized study investigated the long-term safety and tolerability of rotigotine transdermal system in early Parkinson's disease (PD). Patients with early-stage idiopathic PD received transdermal rotigotine for up to 6 years
S R Schreglmann et al.
Parkinsonism & related disorders, 18(2), 207-209 (2011-10-28)
Dopaminergic drugs are the mainstay of treatment for restless legs syndrome (RLS). We analyzed the frequency and clinical characteristics of impulse control disorders (ICD) in patients with RLS on transdermal rotigotine treatment. Retrospective case series at a university movement disorder
Liesbet Ghys et al.
Expert opinion on pharmacotherapy, 12(13), 1985-1998 (2011-07-28)
The aim of this research is to characterize further the potential motor and non-motor benefits of rotigotine reported in the double-blind, placebo-controlled RECOVER trial primary publication, by performing a post hoc exploratory analysis of patient status (symptom improvement/worsening). Full RECOVER
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持